IBC-Ab002
- Weizmann Institute
- No comments
The antibody IBC-Ab002, based on research by Prof. Michal Schwartz of the Weizmann Institute of Science, was tested in 40 patients in the early stages of the disease. The treatment was found to be safe and tolerable at the doses tested and led to changes in biomarkers, but